Skip to main content
menu sluit menu
Home Home
Login
Main navigation
  • Library
  • Calendar
  • e-Learning
  • News
    • Veterinary News In this section you find veterinary news
    • Recent Additions All content that was recently added to the IVIS library
  • Get involved
    • Donate Support IVIS, make a donation today
    • Media kit Promote your e-learning & events on IVIS
    • Add your e-learning & events to the IVIS calendar
    • Publish on IVIS Publish your work with us
  • About
    • Mission Our Mission Statement
    • What we do More info about IVIS and what we do
    • Who we are More info about the IVIS team
    • Authors See list of all IVIS authors and editors
  • Contact
User tools menu
User tools menu
Main navigation
  • Library
  • Calendar
  • e-Learning
  • News
    • Veterinary News In this section you find veterinary news
    • Recent Additions All content that was recently added to the IVIS library
  • Get involved
    • Donate Support IVIS, make a donation today
    • Media kit Promote your e-learning & events on IVIS
    • Add your e-learning & events to the IVIS calendar
    • Publish on IVIS Publish your work with us
  • About
    • Mission Our Mission Statement
    • What we do More info about IVIS and what we do
    • Who we are More info about the IVIS team
    • Authors See list of all IVIS authors and editors
  • Contact
Follow IVIS
  • Twitter
  • Facebook
Support IVIS

Breadcrumb

  1. Home
  2. Library
  3. Recent Advances in Small Animal Reproduction
  4. Clinical Use of Anti-Progestins in the Bitch
Recent Advances in Small Animal Reproduction - Concannon P.W.
Back to Table of Contents
Add to My Library
Close
Would you like to add this to your library?

Get access to all handy features included in the IVIS website

  • Get unlimited access to books, proceedings and journals.
  • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
  • Bookmark your favorite articles in My Library for future reading.
  • Save future meetings and courses in My Calendar and My e-Learning.
  • Ask authors questions and read what others have to say.
Sign in Register
Comments
Print this article
Share:
  • Facebook
  • LinkedIn
  • Mail
  • Twitter

Clinical Use of Anti-Progestins in the Bitch

Author(s):
Fieni F.,
Bruyas J.F.,
Battut I. and
Tainturier D.
In: Recent Advances in Small Animal Reproduction by Concannon P. et al.
Updated:
FEB 23, 2001
Languages:
  • EN
  • ES
Back to Table of Contents
Add to My Library
Close
Would you like to add this to your library?

Get access to all handy features included in the IVIS website

  • Get unlimited access to books, proceedings and journals.
  • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
  • Bookmark your favorite articles in My Library for future reading.
  • Save future meetings and courses in My Calendar and My e-Learning.
  • Ask authors questions and read what others have to say.
Sign in Register
Print this article
SHARE:
  • Facebook
  • LinkedIn
  • Mail
  • Twitter
    Read

    Introduction

    In the bitch, progesterone plays a critical role in the establishment and maintenance of pregnancy. At the onset of estrus, serum progesterone rises. Progesterone permits the maturation of uterine cells so as to prepare them for implantation. After fecundation, progesterone controls uterine secretions which nourish the embryo until implantation between days 18 and 23. Lastly, progesterone inhibits uterine contractions throughout the 65th or so days of pregnancy.

    This physiological regulation of pregnancy by progesterone is the reason that anti-progestins can be used for pregnancy termination and the induction of parturition in dogs. At least one anti-progestin is available for clinical use in dogs in selected European countries.

    Antihormones and Antiprogestins

    Antihormones have the ability to bind particular hormonal receptors without eliciting a hormonal message or action (Fig. 1). Often, antihormones increase the synthesis and plasma concentrations of other hormones by the inhibition of the normal feedback control of those hormones.

    Antiprogestins are synthetic steroids which bind with great affinity to progesterone receptors without any of the effects of progesterone. In bitches, two antiprogestins have been studied: mifepristone (RU 486) and aglepristone (RU 534) (Fig. 2).

    Binding competition between progesterone and aglepristone for the progesterone receptors and consequences
    Figure 1. Binding competition between progesterone and aglepristone for the progesterone receptors and consequences.

    Chemical structures of aglepristone and progesterone
    Figure 2. Chemical structures of aglepristone and progesterone.

    Mifepristone is a progesterone and glucocorticoid antagonist. It is more potent as an anti-progestin than as an anti-corticoid. In the absence of progesterone or cortisol, mifepristone can have a moderate agonistic effect [1]. Mifepristone was developed by Roussel Uclaf laboratories for application in humans. In pregnant women, mifepristone (RU486) is able to interrupt early pregnancy in 80% of cases without any major side effects [2]. To improve its efficacy, mifepristone is currently used in combination with low doses of prostaglandin analogs such as misoprostol. The efficacy of combined treatment (mifepristone plus misoprostol) is 96% [3]. Mifepristone has been demonstrated to induce direct luteolysis [4] and has an anticorticoid activity [5]. This drug is not available for veterinary use.

    Aglepristone is an antiprogestin recently developed by Roussel Uclaf veterinary research specifically for animal use. It is available in France, Norway and Sweden under the name of Alizine ® distributed by Virbac laboratories (Carros, France) (Fig. 3). Aglepristone competes with progesterone for uterine receptors with a fixating rate of 3 (versus 1 for progesterone) in the bitch [6]. In the queen, the fixating rate is 9.

    Alizine® - commercial presentation
    Figure 3. Alizine® - commercial presentation.

    Pregnancy Termination

    Mifepristone

    In pregnant bitches, mifepristone was effective if administered after day 30 of gestation [7-14]. The protocol used was the oral administration of 2.5 mg/kg, twice a day for 4 to 5 days. Pregnancy was terminated without side effects within 3 to 4 days after treatment.

    Aglepristone

    This drug can be used for pregnancy termination from mating date until 45 days after mating (Fig. 4).

    Protocol of Alizine ® administered twice, 24 h apart, for pregnancy termination in dogs
    Figure 4. Protocol of Alizine ® administered twice, 24 h apart, for pregnancy termination in dogs. Mating on the day after ovulation in mid-estrus will normally result in a pregnancy with parturition occurring 62 days later. Alizine can be used any time up to day 45 for safe effective termination of pregnancy, including early pregnancy between Day 0 and 21 after mating. In mid pregnancy it can be used in bitches in which an unwanted pregnancy has been confirmed by ultrasound between Day 22 and 30. In contrast, proposed uses of estrogens are only effective between Days 0 - 3. The use of prostaglandin for pregnancy termination is often limited to Days 30 - 45 following pregnancy diagnosis, because of the need for multiple, frequent administrations and side-effects.

    Protocol - Bitches are injected subcutaneously with 0.33 ml/kg/day repeated once 24 hours later. The preparation is an oily-alcohol solution containing 30 mg of aglepristone per ml. (Alizine ®).

    Efficacy - In a control study (104 bitches), the early administration of aglepristone after mating (Day 0 - Day 25) always resulted in abortion (confidence interval from 90% to 100% (P<0,05)). Its later administration (Day 26 - Day 45) induced abortion in less than seven days in 95.7 % of cases studied (confidence interval from 89% to 100% (P<0,05)) [8] (Table 1).

    Table 1. Rate of Pregnancy Termination after Aglepristone Administration

    Study

    Early pregnancy termination Day 0 to day 25

    Mid pregnancy termination Day 26 to day 45

    At Vet School

    100 % (35/35)

    95.7 % (66/69)

    At Practitionner's

    100 % (139/139)

    94.4 % (117/124)

    Similar results were obtained in a field-trial study on mid-pregnancy termination (124 bitches). Fourteen days after the first injection of aglepristone, 94.4% of the bitches had no foetal image during an ultrasonography examination of the uterus (confidence interval from 89% to 98% (P< 0,05)). Embryonic resorption occurred for bitches treated in early pregnancy. In mid pregnancy fetal expulsion occurred 4 days after the first aglepristone injection for 50% of the bitches and within 7 days for all the bitches. It is clinically important to confirm the efficacy of the treatment. An ultrasonographic exam of the uterus must be performed 8 days after treatment in mid-pregnancy or 20 days after treatment in early pregnancy.

    Safety - Administration of aglepristone can induce a localised inflammatory reaction which disappears within two weeks. This may be due to the oily-alcohol solution of Alizine ®. To prevent this reaction, practitioners are advised to massage the skin at the injection site. Early pregnancy termination, (before 25 days post mating), does not induce either clinical observation or modification of the ultrasonographic image of the uterus.

    Termination in mid-pregnancy induces foetal expulsion. Brown mucoid vaginal discharges are observed 24 hours before foetal expulsion and continued for 3 to 5 days. During the abortion itself, some clinical signs such as slight depression, transitory anorexia, mammary gland congestion can be present. Such signs are also often observed at physiological parturition time and in late pregnancy termination with prostaglandins or antiprolactin-drugs [9].

    There are no repercussions on reproductive function apart from the fact that, in some bitches, there is a decrease in the interoestrous interval from one to three months [8]. Consequently bitches may be observed returning to estrus as early as 45 days after pregnancy termination.

    Hormonal Variation - aglepristone does not modify plasma concentrations of progesterone, prostaglandins, oxytocin or cortisol within 24 hours after its administration but induces an increase in concentrations of prolactin within 12 hours in bitches treated in mid pregnancy (Fig. 5). This can explain the mammary gland congestion typically observed after mid-pregnancy termination. Shortening of the interoestrous interval and prolactin release seems to prove a direct or indirect action of aglepristone on hypothalamic-pituitary axis. As an abortifacient, aglepristone acts like a progesterone antagonist, at the uterus level and does not have direct and immediate luteolysis properties. Termination of pregnancy occurs in the presence of high plasma progesterone concentrations (Fig. 6). Foetal expulsions in late pregnancy termination are accompanied by an increased prostaglandin F metabolites (PGFM) concentrations and decreased progesterone concentrations, however, oxytocin and cortisol remain at a basal level.

    Plasma prolactin concentrations, demonstrating specific prolactin discharge observed at 12 hours of aglepristone administration for mid-pregnancy termination
    Figure 5. Plasma prolactin concentrations, demonstrating specific prolactin discharge observed at 12 hours of aglepristone administration for mid-pregnancy termination.

    Mean (± SD) peripheral plasma concentrations of progesterone for bitches treated in mid-pregnancy
    Figure 6. Mean (± SD) peripheral plasma concentrations of progesterone for bitches treated in mid-pregnancy. Time E was the mean foetal expulsion time.

    Parturition Induction

    Considering the major role progesterone plays in maintaining pregnancy, it follows that antiprogestin can be used to induce parturition. In pregnant women, it has been demonstrated that mifepristone (RU 486) induces uterine contractions and cervix maturation [13]. Used at term, administration of mifepristone induces an effective labor, within 72 hours, in 58% of treated women versus 22% in the control group [11]. In bitches, after 56 days of pregnancy, mifepristone induced parturition between 26 and 70 hours [6,15,16]. Some bitches could not expel the fetuses and a caesarean was performed. For others, expulsion time was between 18 and 45 hours. In addition, the experimental termination of pregnancy after 55 days with aglepristone resulted in the expulsion of live pups [8].

    Protocol - To induce parturition, bitches are injected subcutaneously with 0.05 ml/kg (15 mg/kg) of >aglepristone (Alizine ®), after 58 days of pregnancy, then 24 hours later and every 2 hours afterwards, with 0.15UI/kg ofoxytocin until the end of parturition.

    Efficacy - Results to date suggest that the mean time of parturition onset is 31.6±3.6 hours after aglepristone administration and mean expulsion duration is 4.5±1.8 hours. As a result, if aglepristone is administered at 8 AM, treated bitches will begin parturition the next day between 2 and 6 PM and will finish between 7 PM and 11 PM.

    Safety - At birth, 93.10% of the pups were alive. Forty-eight hours later, the survival rate was 86.21%. Mortality rates were comparable to those observed under natural conditions [17]. This confirms the safety of aglepristone [9,10] and the possibility of the practical use of such a protocol.

    Hormonal Variation - Progesterone peripheral plasma concentrations increase after injection of aglepristone and bitches finish parturition with a progesterone concentration higher than 8 nmol/L. This increase can be due to the binding of progesterone receptors by aglepristone in place of natural hormone. The increase in plasma progesterone concentrations may also be due to an hypothalamic effect of aglepristone on GnRH neurons that results in increased pituitary secretions (FSH and LH) which might stimulate corpora lutea cells. A similar initial increase in progesterone concentrations was observed in the induction of parturition in sheep using mifepristone [12].

    Administering aglepristone does not induce a direct or indirect luteolysis effect and does not modify plasma concentrations of oxytocin or cortisol during the first 24 hours. Four hours after aglepristone administration, PGFM concentrations significantly increase, but after the initial increase, PGFM concentrations remain at a low levels. The authors confirm that antiprogestin administered at the end of pregnancy does not induce a peak of prostaglandin-F2 alpha as has physiologically been observed at parturition time.

    Back to Table of Contents
    Add to My Library
    Close
    Would you like to add this to your library?

    Get access to all handy features included in the IVIS website

    • Get unlimited access to books, proceedings and journals.
    • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
    • Bookmark your favorite articles in My Library for future reading.
    • Save future meetings and courses in My Calendar and My e-Learning.
    • Ask authors questions and read what others have to say.
    Sign in Register
    Print this article
    References

    1. Winer N, Lopez P, Sagot P, et al. Bases fondamentales et applications obstétricales de la Mifépristone ou RU 486 (IVG exclues). Revue Française Gynécologie et d’Obstétrique 1993; 88 2: 73-77. - PubMed -

    ...
    Show all
    Comments (0)

    Ask the author

    0 comments
    Submit
    Close
    Would to like to further discuss this item?

    Get access to all handy features included in the IVIS website

    • Get unlimited access to books, proceedings and journals.
    • Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
    • Bookmark your favorite articles in My Library for future reading.
    • Save future meetings and courses in My Calendar and My e-Learning.
    • Ask authors questions and read what others have to say.
    Sign in Register
    About

    How to reference this publication (Harvard system)?

    Fieni, F. et al. (2001) “Clinical Use of Anti-Progestins in the Bitch”, Recent Advances in Small Animal Reproduction. Available at: https://www.ivis.org/library/recent-advances-small-animal-reproduction/clinical-use-of-anti-progestins-bitch (Accessed: 09 June 2023).

    Affiliation of the authors at the time of publication

    École Nationale Veterinaire de Nantes, Nantes, France

    Author(s)

    • Fieni F.

      Professor Editorial Director of Vet Repro
      DMV PhD Agrégé Dipl ECAR
      École Nationale Veterinaire de Nantes,
      Read more about this author
    • J.F. Bruyas

      Bruyas J.F.

      Assistant Professor
      DMV, PhD, Agrege, Dipl. ECAR
      Biotechnology of Reproduction and Pathology, Department of Clinical Sciences, École Nationale Veterinaire de Nantes,
      Read more about this author
    • Battut I.

      DMV PhD Agrege Dipl ECAR
      Biotechnology of Reproduction and Pathology, Department of Clinical Sciences, École Nationale Veterinaire de Nantes,
      Read more about this author
    • Tainturier D.

      Professor
      DMV PhD Agrege Dipl ECAR
      Biotechnology of Reproduction and Pathology, Department of Clinical Sciences, École Nationale Veterinaire de Nantes,
      Read more about this author

    Copyright Statement

    © All text and images in this publication are copyright protected and cannot be reproduced or copied in any way.
    Related Content

    Readers also viewed these publications

    • Journal Issue

      Anestesia - Argos N°248, Mayo 2023

      MAY 20, 2023
    • Journal Issue

      Dermatología - Argos N°247, Abril 2023

      In: Argos
      APR 22, 2023
    • Journal Issue

      Veterinary Evidence - Vol 8 N°1, Jan-Mar 2023

      In: Veterinary Evidence
      MAR 19, 2023
    • Proceeding

      LAVC - Annual Conference - Lima, 2022

      By: Latin American Veterinary Conference
      MAR 18, 2023
    • Journal Issue

      Cirugía de urgencias - Argos N°246, Marzo 2023

      In: Argos
      MAR 10, 2023
    • Proceeding

      LAVC - Annual Conference - Lima, 2021

      By: Latin American Veterinary Conference
      FEB 19, 2023
    • Journal Issue

      Veterinary Evidence - Vol 7 N°4, Oct-Dec 2022

      In: Veterinary Evidence
      FEB 05, 2023
    • Journal Issue

      Patología cardiaca - Argos N°245, Enero/Febrero 2023

      In: Argos
      JAN 30, 2023
    • Proceeding

      SFT - Theriogenology Annual Conference - Bellevue, 2022

      By: Society for Theriogenology
      JAN 10, 2023
    • Journal Issue

      Urgencias y cuidados intensivos - Argos N°244, Diciembre 2022

      In: Argos
      DEC 31, 2022
    • Journal Issue

      Israel Journal of Veterinary Medicine - Vol. 77(4), Dec. 2022

      In: Israel Journal of Veterinary Medicine
      DEC 31, 2022
    • Proceeding

      ISCFR-EVSSAR Symposium - Italy 2022

      By: International Symposium on Canine and Feline Reproduction
      DEC 02, 2022
    • Journal Issue

      Patología endocrina - Argos N°243, Noviembre 2022

      In: Argos
      NOV 27, 2022
    • Proceeding

      ACVIM & ECEIM - Consensus Statements

      By: American College of Veterinary Internal Medicine
      NOV 11, 2022
    • Journal Issue

      Traumatología y neurología - Argos Nº242, Octubre 2022

      In: Argos
      NOV 10, 2022
    • Chapter

      Tibia and Tarsus

      In: Current Techniques in Small Animal Surgery (5th Edition)
      NOV 07, 2022
    • Chapter

      Femur and Stifle Joint

      In: Current Techniques in Small Animal Surgery (5th Edition)
      OCT 28, 2022
    • Journal Issue

      Medicina felina - Argos Nº241, Septiembre 2022

      In: Argos
      OCT 24, 2022
    • Chapter

      Sacroiliac Joint, Pelvis, and Hip Joint

      In: Current Techniques in Small Animal Surgery (5th Edition)
      OCT 17, 2022
    • Journal Issue

      Veterinary Evidence - Vol 7 N°2, Apr-Jun 2022

      In: Veterinary Evidence
      OCT 07, 2022
    • Journal Issue

      Veterinary Evidence - Vol 7 N°3, Jul-Sep 2022

      In: Veterinary Evidence
      OCT 04, 2022
    • Chapter

      Amputation of the Forelimb

      In: Current Techniques in Small Animal Surgery (5th Edition)
      OCT 02, 2022
    • Journal Issue

      Israel Journal of Veterinary Medicine - Vol. 77(3), Sep. 2022

      In: Israel Journal of Veterinary Medicine
      SEP 30, 2022
    • Chapter

      Carpus, Metacarpus, and Phalanges

      In: Current Techniques in Small Animal Surgery (5th Edition)
      SEP 26, 2022
    • Chapter

      Radius and Ulna

      In: Current Techniques in Small Animal Surgery (5th Edition)
      SEP 16, 2022
    • Load more
    Back To Top
    Become a member of IVIS and get access to all our resources
    Create an account
    Sign in
    Leading the way in providing veterinary information
    About IVIS
    • Mission
    • What we do
    • Who we are
    Need help?
    • Contact
    Follow IVIS
    • Twitter
    • Facebook
    International Veterinary Information Service (IVIS) is a not-for-profit organization established to provide information to veterinarians, veterinary students, technicians and animal health professionals worldwide using Internet technology.
    Support IVIS
    © 2023 International Veterinary Information Service
    • Disclaimer
    • Privacy Policy